Surging mpox cases in East, West and Central Africa prompted the World Health Organization to once again make the infection a ...
When an outbreak of mpox first hit the United States in 2022, a vaccine called Jynneos was available to help protect the most ...
It’s déjà vu for Siga Technologies and its smallpox antiviral Tpoxx. At an interim analysis of a second mpox trial, the drug ...
Siga Technologies' antiviral drug tecovirimat did not reduce the time to lesion resolution or have an effect on pain among ...
As a second wave of the viral disease looms, Rutgers Health researchers call for more studies on long-term immunity.
As a result of the preliminary STOMP data – which gave the chances of a positive outcome from the study at less than 1% – the ...
After African countries struggled to get testing kits during the COVID-19 pandemic, officials vowed to make the continent ...
The antiviral drug tecovirimat did not reduce the time to lesion resolution or have an effect on pain among adults with mild ...
STOMP is a randomized, controlled, double-blind trial to evaluate the safety and effectiveness of Tpoxx for treating mpox. In ...